Neuroestimulantes naturales: de rituales ancestrales a terapias de vanguardia
Natural neurostimulants: from ancestral rituals to cutting-edge therapies
DOI:
https://doi.org/10.29105/cienciauanl29.138-5Palabras clave:
5-metoxi-N, N-dimetiltriptamina, dimetiltriptamina, psilocibina, trastornos mentales., 5-methoxy-N, N-dimethyltryptamine, dimethyltryptamine, psilocybin, mental disorders.Resumen
La psilocibina, presente en los “hongos mágicos”, y la 5-MeO-DMT, secretada por el sapo Incilius alvarius, fueron empleadas ancestralmente en rituales espirituales en México. Hoy, la ciencia las reconoce como terapias prometedoras contra depresión, ansiedad, estrés postraumático y adicciones resistentes a tratamientos convencionales. Actúan sobre receptores de serotonina y estimulan la neuroplasticidad, favoreciendo la adaptación y la superación de patrones mentales negativos. Aunque se requieren más estudios clínicos, su uso ancestral inspira terapias innovadoras que integran tradición y ciencia para mejorar el bienestar emocional (Kishon et al., 2024).
Abstract
Psilocybin, found in “magic mushrooms,” and 5-MeO-DMT, secreted by the Incilius alvarius toad, were ancestrally used in spiritual rituals in Mexico. Today, science recognizes them as promising therapies for depression, anxiety, post-traumatic stress disorder, and addictions resistant to conventional treatments. They act on serotonin receptors and stimulate neuroplasticity, promoting adaptation and the overcoming of negative mental patterns. Although further clinical studies are needed, their ancestral use inspires innovative therapies that integrate tradition and science to improve mental health (Kishon et al., 2024).
Descargas
Citas
Kishon, Ronit, Modlin, Nadav L., Cycowicz, Yael M., et al. (2024). A rapid narrative review of the clinical evolution of psychedelic treatment in clinical trials, NPJ Mental Health Research, 3(1), 33, https://doi.org/10.1038/s44184-024-00068-9 DOI: https://doi.org/10.1038/s44184-024-00068-9
Nichols, David, E. (2020). Psilocybin: from ancient magic to modern medicine. The Journal of Antibiotics, 73(10), 679-686, https://doi.org/10.1038/s41429-020-0311-8 DOI: https://doi.org/10.1038/s41429-020-0311-8
Reckweg, Johannes T., van Leeuwen, Cees J., Henquet, Cécile, et al. (2023). A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N, N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression, Frontiers in Psychiatry, 14, 1133414, https://doi.org/10.3389/fpsyt.2023.1133414 DOI: https://doi.org/10.3389/fpsyt.2023.1133414
Wang, Sheng-M., Kim, Sunghwan, Choi, Won-S., et al. (2024). Current understanding on psilocybin for major depressive disorder: a review focusing on clinical trials, Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology, 22(2), 222-231, https://doi.org/10.9758/cpn.23.1134 DOI: https://doi.org/10.9758/cpn.23.1134
Yao, Yuan, Guo, Dan, Lu, Tang-S., et al. (2024). Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis, Psychiatry Research, 335, 115886, https://doi.org/10.1016/j.psychres.2024.115886 DOI: https://doi.org/10.1016/j.psychres.2024.115886
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2026 Armando Ordaz Hernández, Misael, Dr. Israel Jesús
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
